GLP-1
PulseAugur coverage of GLP-1 — every cluster mentioning GLP-1 across labs, papers, and developer communities, ranked by signal.
- developed by Ozempic 90%
- instance of Wegovy 90%
- instance of semaglutide 90%
- instance of tirzepatide 70%
- used by Ozempic 70%
- used by Wegovy 70%
- instance of Ozempic 70%
- used by Centers for Medicare and Medicaid Services 70%
- invested in The Cigna Group 70%
- other Centers for Medicare and Medicaid Services 60%
- affiliated with Centers for Medicare and Medicaid Services 60%
- affiliated with Ozempic 50%
8 day(s) with sentiment data
-
New benchmark reveals hindsight bias in clinical LLM reasoning
Researchers have developed a new benchmark to measure hindsight bias in large language models when reasoning about clinical temporal data. The benchmark, comprising 171 case reports from PubMed Central, evaluates how mo…
-
US employers face 8.2% healthcare cost jump in 2027, impacting employee paychecks
Employers are projected to face an 8.2% increase in healthcare costs per employee in 2027, marking the fifth consecutive year of significant rises. This surge is expected to lead to higher paycheck deductions for employ…
-
Mastodon posts cover CSS for foldables and kids' weight-loss drugs
This cluster covers two distinct topics from Mastodon posts: one discusses designing websites for dual-screen and foldable devices using CSS, and the other explores the current knowledge and implications of using GLP-1 …
-
Strategies to Maintain Weight Loss After GLP-1 Drug Discontinuation
Weight regain is common after discontinuing GLP-1 drugs, with studies indicating that approximately two-thirds of lost weight can return within a year. A physician has outlined five evidence-based strategies to help ind…
-
GLP-1 Drug Costs in 2026: From $25 Copays to $1,349 Retail
A Forbes article outlines the various costs associated with obtaining GLP-1 drugs in 2026, noting that one in eight US adults currently uses these medications. The report details that most users do not pay the full reta…
-
GLP-1s and GenAI Could Tackle Healthcare Affordability Crisis
Generative AI and GLP-1 medications, when combined, offer a potential solution to the escalating healthcare affordability crisis in the United States. Chronic diseases, which account for a significant portion of healthc…
-
Baldness drugs emerge as Wall Street's next major investment opportunity
Wall Street is increasingly focusing on the development of new baldness treatments, viewing them as a significant investment opportunity akin to the recent boom in obesity drugs. Companies like Veradermics, Absci Corp.,…
-
MindRank advances AI-discovered GLP-1 drug to Phase III trials in 4.5 years
MindRank has advanced its primary oral GLP-1 candidate drug into Phase III clinical trials. This significant milestone was achieved in approximately four and a half years, with a total research investment of around $23 …
-
IHH Healthcare CEO launches longevity program amid Asia's aging population
IHH Healthcare, led by CEO Prem Kumar Nair, is launching a new preventive health and longevity program called "Healthspan" to address the growing issue of lifestyle diseases in Asia's aging population. The initiative, c…
-
Medicare GLP-1 discount program excludes patients with certain medical conditions
A new Medicare pilot program offering GLP-1 medications for weight loss at a reduced cost of $50 per month has encountered issues with patient eligibility. While intended to help those struggling with the high price of …
-
TikTok profits from illegal drug ads despite policy bans
TikTok is profiting from advertisements that promote illegal drugs, including cocaine, opioids, and controlled medications like Xanax and Percocet. Despite TikTok's policies against such content, numerous accounts are a…
-
Nestlé uses AI to develop products for weight loss drug users
Nestlé is leveraging artificial intelligence and nutritional research to develop new products for consumers using GLP-1 weight loss drugs. The company aims to transform the growing popularity of these medications from a…
-
Drug prices fall as Biden's Medicare negotiation and competition outweigh Trump's deals
Recent data indicates a decrease in U.S. prescription drug prices, with a 0.8% drop in July and a 3.1% decrease year-over-year. While former President Donald Trump has claimed credit for this trend, attributing it to hi…
-
Chinese team develops 'smart' diabetes probiotic to rival Ozempic
A Chinese research team has developed an engineered probiotic, named Gift, designed to manage diabetes. This probiotic can detect high blood sugar levels and automatically release the hormone GLP-1, which lowers blood g…
-
GLP-1 drugs show promise for hormonal disorder PMOS
GLP-1 drugs, commonly used for weight loss and diabetes, are showing significant promise in treating polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder affecting women. Early research and patient testi…
-
GLP-1 drugs pose hidden risk of bone and muscle loss, experts warn
GLP-1 medications, while effective for weight loss and improving cardiovascular health, carry a hidden risk of significant muscle and bone density loss. This can increase fracture risk, particularly in older adults and …
-
AI could help combat global fatty liver disease epidemic
Artificial intelligence may offer a solution to the growing global epidemic of fatty liver disease, which affects approximately 30 percent of adults worldwide and can lead to liver failure, cardiovascular disease, and c…
-
Tech Giants Face Lawsuits Over Social Media Addiction; GLP-1 Drugs Show Brain Health Promise
A recent court ruling allows thousands of lawsuits alleging social media addiction to proceed against tech giants like Meta. Separately, researchers are exploring the potential of GLP-1 drugs, such as Ozempic, to treat …
-
GLP-1 Drugs Boost Women's Employment More Than College Degrees, Study Finds
A study from Harvard University, published by the National Bureau of Economic Research, suggests that GLP-1 drugs, such as Ozempic and Wegovy, have a greater impact on increasing women's employment rates than obtaining …
-
GLP-1 drugs show surprising benefits beyond weight loss
GLP-1 medications, commonly known for weight loss and type 2 diabetes treatment, are demonstrating a range of surprising health benefits beyond their initial applications. Recent trials indicate these drugs can protect …